Showing 431-440 of 5909 results for "".
Alcon Launches PanOptix Pro in US
https://modernod.com/podcasts/eyewire-news-the-podcast/alcon-launches-panoptix-pro-in-us/37078/Alcon introduces its next-generation trifocal IOL; Alcon announces a deal to advance its clinical-stage allogeneic cell therapy; and Bausch + Lomb announces a voluntary recall of IOLs on its enVista platform. Learn more about your ad choices. Visit megaphone.fm/adchoicesFDA Expands Product Label for Iluvien
https://modernod.com/podcasts/eyewire-news-the-podcast/fda-expands-product-label-for-iluvien/37076/Iluvien receives a major label expansion; Bausch and Lomb launches a new orthokeratology lens fitting system; and several updates are announced in development wet AMD candidates. Learn more about your ad choices. Visit megaphone.fm/adchoices88. Decoding Headaches: When Vision is the Culprit
https://modernod.com/podcasts/four-eyes/88-decoding-headaches-when-vision-is-the-culprit/37038/Headaches are one of the most common patient complaints—but how do you know if they’re vision-related? In this episode, Dr. Kar and Dr. Bilkhu break down different types of headaches, key signs that point to a visual cause, and when to refer for urgent medical attention. We also dive into treatmentAlcon Voyager DSLT Fully Launched in US
https://modernod.com/podcasts/eyewire-news-the-podcast/alcon-voyager-dslt-fully-launched-in-us/37072/Alcon launches the first DSLT device in thee US; the FDA approves an expanded label for Astellas Pharma's geographic atrophy drug Izervay; and New World Medical received FDA clearance for the VIA360 Surgical System. Learn more about your ad choices. Visit megaphone.fm/adchoicesAAO Opposes NIH Research Funding Proposal
https://modernod.com/podcasts/eyewire-news-the-podcast/aao-opposes-nih-research-funding-proposal/37071/The AAO responds to a proposal by the NIH to limit indirect funding for research projects; Lumenis launches a new device to address lower lid laxity and impaired blinking; and AI Optics receives FDA clearance for a handheld retinal imaging system. Learn more about your ad choices. Visit megaphone.fmNorlase Launches First Pattern Scanning LIO
https://modernod.com/podcasts/eyewire-news-the-podcast/norlase-launches-first-pattern-scanning-lio/37069/The world’s first and only pattern scanning laser indirect ophthalmoscope is approved in the US and Europe; the European Commission approves a biosimilar to Eylea; and we review several clinical updates in the development of ophthalmic drugs. Learn more about your ad choices. Visit megaphone.fm/adchZeiss MEL 90 Approved by FDA
https://modernod.com/podcasts/eyewire-news-the-podcast/zeiss-mel-90-approved-by-fda/37068/Zeiss receives a major approval for its new excimer laser; Bausch + Lomb makes two deals to bolster its pipeline in glaucoma and geographic atrophy; and Rayner announces the full European launch of its RayOne Galaxy IOLs. Learn more about your ad choices. Visit megaphone.fm/adchoicesGlaukos Submits NDA for Epi-On CLX Candidate
https://modernod.com/podcasts/eyewire-news-the-podcast/glaukos-submits-nda-for-epi-on-clx-candidate/37066/Glaukos submits a new drug application to the FDA for its next-generation cross-linking therapy; Regeneron releases phase 3 results for Eylea HD for RVO; and Regeneron acquires a clinical stage biotech making ocular delivery technology for retinal disorders. Learn more about your ad choices. Visit mB+L Bolsters Glaucoma Offerings with Elios Acquisition
https://modernod.com/podcasts/eyewire-news-the-podcast/bl-bolsters-glaucoma-offerings-with-elios-acquisition/37063/Bausch + Lomb makes an acquisition to expand its glaucoma offerings; Roche gets a major approval in Europe for Vabysmo; and EssilorLuxottica buys a maker of noninvasive ophthalmic medical devices. Learn more about your ad choices. Visit megaphone.fm/adchoicesPhase 3 Results for Novel Sedation Tablet
https://modernod.com/podcasts/eyewire-news-the-podcast/phase-3-results-for-novel-sedation-tablet/37062/New phase 3 data is released for a non-opioid sedation tablet; the first patient is dosed in the phase 3 trial of EyePoint’s wet AMD candidate; and Outlook receives a reimbursement decision in the UK for its wet AMD treatment. Learn more about your ad choices. Visit megaphone.fm/adchoices